Early diagnosis and successful long-term management of a rare, severe lysosomal acid lipase deficiency/Wolman disease patient: Infancy to age five

Author:

Cossette Antoine1,Castilloux Julie2,Bouffard Chantal3,Laflamme Julie4,Faure Christophe5,Benlamlih Sami1,Abel Florian6,Beecroft Michael6,Francis Mira6,Drouin Régen7

Affiliation:

1. ULaval, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada

2. Pediatric Gastroenterology Division, Department of Pediatrics, CHU de Québec – ULaval, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada

3. Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, CHUS Research Center, Université de Sherbrooke, Sherbrooke, Quebec, Canada

4. Pediatric Palliative Care Division, Department of Pediatrics, CHU de Québec – ULaval, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada

5. Pediatric Gastroenterology, Sainte-Justine Hospital, Montréal, Quebec, Canada

6. Alexion Pharmaceuticals, Inc, Boston, Massachusetts, USA

7. Division of Medical Genetics, Department of Pediatrics, CHU de Québec – ULaval, and Research Center of the CHU de Québec – ULaval, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada

Abstract

BACKGROUND: This report describes a unique case of long-term survival of a young girl who was diagnosed with severe, rapidly progressive lysosomal acid lipase deficiency (LAL-D; historically “Wolman disease”) at three months of age and began receiving therapeutic interventions at four months of age. This disease involves rapidly progressive multisystemic impairments and limited survival (6–12 months) without treatment. METHODS: Case report taking into account clinical aspects and patient management including a semi-structured interview with the main family caregiver. RESULTS: Presentation at two months of age: severe malnutrition and chronic diarrhea; hypoalbuminemia; low iron, vitamin A, and vitamin D levels; high triglyceride levels; profound anemia; thrombocytopenia; adrenal calcifications; and mild hepatosplenomegaly. Enzyme replacement therapy (ERT) with sebelipase alfa, parenteral nutrition, and a low-fat diet began at age four months. The patient has received sebelipase alfa for >5 years with good tolerability and is thriving, with a body mass index of 16.35 kg/m2 (80th percentile) despite a stature delay (height <3rd percentile), and mild developmental delay. Optimal medical management requires that family caregivers and health professionals have the knowledge and skills to provide appropriate care and supports multidisciplinary teams through transfer of knowledge to all stakeholders. Effective coordination of services and activities related to child health and development, including navigation of administrative and financial barriers, is also imperative. CONCLUSIONS: Formerly fatal in untreated infants, severe LAL-D, when diagnosed early, can be promptly and effectively treated by combining sebelipase alfa ERT, modified diet, involvement of family caregivers, and multidisciplinary team collaboration.

Publisher

University of Toronto Press Inc. (UTPress)

Subject

Religious studies,Cultural Studies

Reference9 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3